(Date:11/20/2009)...ries have an opportunity to take the lead in two s...niversity of Valencia (UV), working together with ...e fabric of the Spanish biotechnology industry. Th...ors have more clout than those in English-speaking...nd plants has been overlooked by the leading count...
(Date:11/20/2009)... Cell Therapeutics, Inc. ...the Ninth Circuit Court of Appeals reversed a U.S.... allowed to pursue all of its claims against The L...ourt for trial. CTI filed a complaint against The...t consultant for CTI,s product TRISENOX, in 2007 s...
(Date:11/19/2009)...ewswire-FirstCall/ -- Omeros Corporation (Nasdaq: ...s for the third quarter ended September 30, 2009. ...ros reported a net loss of $3.9 million, or $1.34 ...on, or $2.54 per share, for the same period in 200...he Company reported a net loss of $15.5 million, o...
(Date:11/19/2009)...WALTHAM, Mass., Nov. 19 Arlington ...d that the leading driver of antibiotic selection ...m activity against gram-positive and gram-negative...an cause nosocomial pneumonia, surveyed European p...ts that provide appropriate coverage against commo...
Breaking Biology Technology:Spanish biotechnology should focus on food and plant sectors to be more competitive 2Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3... Inc., a subsidiary of,Eisai Corporation of North ...ulti-centered Phase II study of its MORAb-009 mono...aluate MORAb-009, plus the chemotherapy drugs,peme...for patients with,mesothelioma. , The primary ...f MORAb-009,as combination therapy with the curren...
...ll/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: A...new Senior Secured Term Loan and Revolving Credit ...ranger, administrative agent and lender for both t...financing includes a delayed draw secured term loa...olving credit facility with a borrowing base deriv...
... the California Institute for Regenerative Medicin... Stemedica Cell Technologies, Inc. ("Stemedic...;D lab and corporate headquarters. , ...9 -- Leadership of the California Institute for Re... two part visit to Stemedica Cell Technologies, In...
Other Biology Technology:Morphotek(R), Inc. Announces Initiation of MORAb-009 Phase II Study in First- Line Treatment of Mesothelioma 2Morphotek(R), Inc. Announces Initiation of MORAb-009 Phase II Study in First- Line Treatment of Mesothelioma 3Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities 2Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities 3Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities 4CIRM Completes Briefing Visit to Stemedica Cell Technologies 2CIRM Completes Briefing Visit to Stemedica Cell Technologies 3Experion RNA StdSens Chips, 10 from Bio-Rad
MiniMACS Separation Unit from Miltenyi Biotec
Experion RNA HighSens Chips, 10 from Bio-Rad
...activated with carbonyl diimidazole chemistry that...e PS10 array contains the same binding chemistry a...hobic barrier coating. These arrays are 8 spot chi...ith one column of a standard 96-well microplate (9...
Biology Products: